Loading clinical trials...
Loading clinical trials...
A Phase II Study of Time-limited Combination of Pirtobrutinib, Venetoclax, and Rituximab in Treatment Naïve Patients With Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) (PRoVen)
Conditions
Interventions
Pirtobrutinib
Venetoclax
+1 more
Locations
8
United States
Beth Israel Deaconess Medical Center (Data Collection Only)
Boston, Massachusetts, United States
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Memoral Sloan Kettering Monmouth
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
Memorial Sloan Kettering Suffolk - Commack
Commack, New York, United States
Memorial Sloan Kettering Westchester
Harrison, New York, United States
Start Date
November 11, 2025
Primary Completion Date
April 11, 2028
Completion Date
April 11, 2028
Last Updated
November 17, 2025
NCT07387471
NCT06510491
NCT01804686
NCT04195633
NCT02269592
NCT05602363
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions